AZ Hopes Coupling GLP-1 Bydureon and SGLT-2 Forxiga Is Paradigm Shift

AstraZeneca hopes positive results from its DURATION-8 trial combining its GLP-1 drug Bydureon and SGLT2 product Forxiga for the first time will spur use – and sales – for each, and open the way for an additional line of defense for type 2 diabetes patients before they are moved onto insulin.